Charles River Laboratories International (NYSE:CRL) Releases FY 2025 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 9.100-9.600 for the period, compared to the consensus estimate of 9.600. The company issued revenue guidance of $3.8 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion.

Analysts Set New Price Targets

Several research firms have commented on CRL. William Blair cut shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Barclays dropped their target price on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Bank of America lowered their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. The Goldman Sachs Group lowered their price target on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Finally, UBS Group reaffirmed a “neutral” rating and issued a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Three equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of “Hold” and an average price target of $197.64.

Charles River Laboratories International Stock Up 1.7 %

Charles River Laboratories International stock opened at $154.63 on Wednesday. Charles River Laboratories International has a 1-year low of $150.79 and a 1-year high of $275.00. The firm has a market capitalization of $7.91 billion, a price-to-earnings ratio of 19.35, a P/E/G ratio of 5.91 and a beta of 1.37. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The firm has a 50 day simple moving average of $174.59 and a 200 day simple moving average of $189.16.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. On average, analysts predict that Charles River Laboratories International will post 10.16 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).